180 related articles for article (PubMed ID: 11081202)
21. Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study.
Kontogeorgos G; Patralexis H; Tran A; Kovacs K; Melmed S
Pituitary; 2000 May; 2(4):245-51. PubMed ID: 11081145
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau tumor suppressor targets to mitochondria.
Shiao YH; Resau JH; Nagashima K; Anderson LM; Ramakrishna G
Cancer Res; 2000 Jun; 60(11):2816-9. PubMed ID: 10850420
[TBL] [Abstract][Full Text] [Related]
23. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.
Corless CL; Kibel AS; Iliopoulos O; Kaelin WG
Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946
[TBL] [Abstract][Full Text] [Related]
24. In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas.
Stefaneanu L; Kovacs K; Horvath E; Lloyd RV
Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):107-13. PubMed ID: 1651583
[TBL] [Abstract][Full Text] [Related]
25. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent.
Ye Y; Vasavada S; Kuzmin I; Stackhouse T; Zbar B; Williams BR
Int J Cancer; 1998 Sep; 78(1):62-9. PubMed ID: 9724095
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity of the von Hippel Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas.
Fogt F; Vortmeyer AO; Stolte M; Mueller E; Mueller J; Noffsinger A; Poremba C; Zhuang Z
Hum Pathol; 1998 Sep; 29(9):961-4. PubMed ID: 9744312
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis.
Kontogeorgos G; Kapranos N; Thodou E; Sambaziotis D; Tsagarakis S
Pituitary; 1999 May; 1(3-4):207-12. PubMed ID: 11081199
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase-2 expression in human pituitary tumors.
Vidal S; Kovacs K; Bell D; Horvath E; Scheithauer BW; Lloyd RV
Cancer; 2003 Jun; 97(11):2814-21. PubMed ID: 12767095
[TBL] [Abstract][Full Text] [Related]
29. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro.
Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W
Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101
[TBL] [Abstract][Full Text] [Related]
30. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region.
Schoenfeld AR; Davidowitz EJ; Burk RD
Int J Cancer; 2001 Feb; 91(4):457-67. PubMed ID: 11251966
[TBL] [Abstract][Full Text] [Related]
31. Expression of von Hippel-Lindau protein in normal and pathological human tissues.
Sakashita N; Takeya M; Kishida T; Stackhouse TM; Zbar B; Takahashi K
Histochem J; 1999 Feb; 31(2):133-44. PubMed ID: 10416685
[TBL] [Abstract][Full Text] [Related]
32. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
34. Coexistence of sporadic cerebellar hemangioblastoma and pituitary null cell adenoma: simultaneous expression of von Hippel-Lindau gene product. Case report.
Shimoda Y; Ogawa Y; Endo H; Watanabe M; Tominaga T
Neurol Med Chir (Tokyo); 2012; 52(8):591-4. PubMed ID: 22976143
[TBL] [Abstract][Full Text] [Related]
35. Composite somatotroph--ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma.
Mazarakis N; Kontogeorgos G; Kovacs K; Horvath E; Borboli N; Piaditis G
Pituitary; 2001 Sep; 4(4):215-21. PubMed ID: 12501971
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor in pituitary adenomas of the gonadotroph cell complex.
Saeger W; Schreiber S; Lüdecke DK
Pathol Res Pract; 2000; 196(11):771-3. PubMed ID: 11186173
[TBL] [Abstract][Full Text] [Related]
37. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
38. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
[TBL] [Abstract][Full Text] [Related]
39. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.
Heaney AP; Curry WJ; Pogue KM; Armstrong VL; Mirakhur M; Sheridan B; Johnston CF; Buchanan KD; Atkinson AB
Pituitary; 2000 Oct; 3(2):67-75. PubMed ID: 11141698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
